Long-term psoriasis clearance reported with deucravacitinib

Plaque psoriasis patients treated with deucravacitinib maintained improvement for up to 2 years, Bristol Myers Squibb announced in a press release.

Long-term results of the global, phase 3, multicenter, randomized, double blind POETYK PSO-1 and POETYK PSO-2 trials were presented at the European Academy of Dermatology and Venereology spring meeting.

After 60 weeks of treatment, PASI75 was maintained in 77.7% of patients, while PGA of 0/1 (clear or almost clear) was maintained in 58.7% of patients.

“These long-term follow up results add to the growing body of evidence for deucravacitinib, a first-in-class, oral, selective allosteric TYK2 inhibitor with a unique mechanism of action, reinforcing its potential to offer patients with moderate to severe plaque psoriasis an oral treatment option that addresses current gaps in care,” Jonathan Sadeh, MD, MSc, senior vice president of immunology and fibrosis development at Bristol Myers Squibb, said in the release.

Most adverse events were mild or moderate, with the most common being nasopharyngitis, upper respiratory tract infection and headache.